Business
GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication
Focus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and
About this update from Genedx Holdings Corp.
[{"type":"text","content":"\nFocus on Inborn Errors of Immunity expands access to exome and genome testing for the known 200,000+ patients in the US 1 impacted by these conditions and opens new opportunities for GeneDx and biopharma partners to accelerate the path to treatment for patients\n\n GAITHERSBURG, Md.--(BUSINESS WIRE)--\nGeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the commercial expansion into Inborn Errors of Immunity (IEI), a group of nearly 500 genetic disorders that impair immune function2, increasing susceptibility to infections, autoimmunity, and inflammatory conditions. The strategic expansion reinforces GeneDx’s mission to improve patient outcomes by providing exome and genome testing solutions for an ever-growing number of patients, now including those with inherited immunological conditions.\n\nWith an expanded commercial focus on IEIs, GeneDx accelerates patient care with the adoption of exome and genome testing, empowering ordering clinicians with more accurate and comprehensive genetic insights to better treat this patient population. Today, clinicians treating IEIs recognize the importance of genetic testing, and with the rapid pace of new gene-disease discovery in IEI1, exome and genome sequencing are better equipped than panel-based testing to stay up to date with new discoveries in this area. Genomic sequencing provides a diagnostic yield of approximately 40% for IEI patients3,4,5 — higher than the 29% yield from multi-gene panels.3\n\nWith superior diagnostic accuracy and growing reimbursement support, the shift toward an exome and genome-first approach accelerates times to an accurate diagnosis and informs personalized treatment decisions such as bone marrow transplantation, gene therapy, biologic supportive therapy, and Ig replacement therapy. Therapies are available for more than 50% of individuals with an IEI.6\n\n“GeneDx’s commercial focus on Inborn Errors of Immunity furthers our commitment to providing patients, families and clinicians with the most comprehensive genetic testing solutions at the times they need it most,” said Britt Johnson, PhD, FACMG, and Senior Vice President of Medical Affairs at GeneDx. “By transitioning from panel-based testing to exome and genome sequencing, GeneDx will improve diagnostic precision, enabling earlier interventions, ...